Microbion

Executive Summary

Microbion is a clinical-stage pharmaceutical company pioneering a novel class of anti-infective compounds that target and eradicate microbial biofilms, addressing difficult-to-treat, chronic, and antibiotic-resistant infections. Based in Bozeman, Montana, the company's lead candidate, pravibismane, is a first-in-class bismuth-based small molecule with anti-inflammatory and immunomodulatory properties. Pravibismane is currently in Phase 2 clinical trials for chronic wound infections, including diabetic foot ulcers, a high unmet need area. The company's technology has the potential to overcome biofilm-associated resistance, a major challenge in infectious disease. With a focused pipeline and a strong scientific foundation, Microbion represents an attractive opportunity in the anti-infective space, though it remains private and early-stage. Key upcoming catalysts include Phase 2 data readouts, potential strategic partnerships, and financing rounds to support further development.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 data readout for pravibismane in diabetic foot ulcer infections60% success
• Q1 2027FDA meeting to discuss Phase 3 trial design75% success
• H1 2027Series C or partnership financing round50% success